Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 31;8(5):8305-8314.
doi: 10.18632/oncotarget.14171.

5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia

Jae-Sook Ahn  1   2 , Hyeoung-Joon Kim  1   2 , Yeo-Kyeoung Kim  1   2 , Seung-Shin Lee  1 , Seo-Yeon Ahn  1 , Sung-Hoon Jung  1 , Deok-Hwan Yang  1 , Je-Jung Lee  1 , Hee Jeong Park  2 , Seung Hyun Choi  2 , Chul Won Jung  3 , Jun-Ho Jang  3 , Hee Je Kim  4 , Joon Ho Moon  5 , Sang Kyun Sohn  5 , Jong-Ho Won  6 , Sung-Hyun Kim  7 , Szardenings Michael  8 , Mark D Minden  9 , Dennis Dong Hwan Kim  9
Affiliations

5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia

Jae-Sook Ahn et al. Oncotarget. .

Abstract

Stem cells display remarkably high levels of 5-hydroxymethylcytosine (5hmC). Both TET2 and IDH1/2 mutations can impair the production of 5hmC, thus decreasing 5hmC levels. TET2 or IDH1/2 mutations are commonly observed in acute myeloid leukemia (AML). However, the implications of 5hmC on survival in normal karyotype AML patients have not been fully evaluated. The 5hmC levels were analyzed in 375 patients using ELISA. The levels of 5hmC in DNA samples were converted to a log scale for the analysis and correlations with TET2 and/or IDH1/2 mutations were evaluated. The median 5hmC level was 0.065% (range 0.001-0.999). Mutation rates were 13.1% for TET2mut, 6.7% for IDH1mut, and 13.9% for IDH2mut. The prevalence of TET2 and/or IDH1/2 was 33.1% (124/375). TET2 and IDH1/2 mutated patients had significantly lower levels of log(5hmC) compared with patients without TET2 or IDH1/2 mutations (p<0.001). With a median follow-up of 55.5 months (range, 0.7-179.8), there was no significant difference in overall survival, event-free survival, and relapse risk according to TET2mut or IDH1/2mut (all, p>0.05). To identify its prognostic value, we sub-classified the levels of 5hmC into tertiles for 5hmC values. However, there was no significant association between the categories of 5hmC levels and survival or relapse risk (all p>0.05). Patients with TET2 or IDH1/2 mutations had lower levels of 5hmC. The 5hmC levels may not be predictive of survival in patients with normal karyotype AML.

Keywords: 5hmC; AML; IDH1/2; TET2; normal karyotype.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. 5-Hydroxymethycytosine (5hmC) levels are decreased in patients with TET2 and IDH mutations
Patients with TET2 A. IDH1/2 B. and TET2 or IDH1/2 C. mutations had significantly lower 5hmC levels than those with the TET2 wild type, IDH1/2 wild type, or both wild types (all P<0.001).
Figure 2
Figure 2. Outcomes of patients with normal karyotype acute myeloid leukemia according to the 5-hydroxymethylcytosine (5hmC) levels
Overall survival A. event-free survival B. and relapse incidence C. are shown.
See this image and copyright information in PMC

References

    1. Esteller M. Epigenetics in cancer. The New England Journal of Medicine. 2008;358:1148–1159. - PubMed
    1. Kroeze LI, van der Reijden BA, Jansen JH. 5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer. Biochimica et Biophysica Acta. 2015;1855:144–154. - PubMed
    1. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333:1300–1303. - PMC - PubMed
    1. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–567. - PMC - PubMed
    1. Chan SM, Majeti R. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia. International Journal of Hematology. 2013;98:648–657. - PMC - PubMed

MeSH terms